
Monday, April 25, 2011
FTIR for Estimating Viable Counts in Beef

Wednesday, April 20, 2011
Latest RMM papers from European Pharmaceutical Review

The risk for patients through spoiled or otherwise adulterated pharmaceuticals has been acknowledged for many centuries and led to the establishment of Good Manufacturing Practice (GMP) and pharmacopoeial guidelines. Besides chemical purity, pharmaceuticals also have to meet microbiological standards, the latter primarily depending on the administration route. Drug products which are injected directly into blood vessels or tissues or that are applied directly into eyes and ears represent a greater infection risk than products which are administered orally or onto intact healthy skin. While parenteral drug products are required to be free from any viable microorganism (USP <71>, Ph. Eur. 2.6.1), oral and topical products are not required to be sterile, but are subject to strict guidelines limiting the number and types of acceptable microorganisms (USP <61> and <62>, Ph. Eur. 2.6.12 and 2.6.13).
Friday, April 15, 2011
Michael Miller Discusses False Positive Testing and Highlights a Case Study Using an Environmental Monitoring RMM

Thursday, April 14, 2011
Claudio Denoya Discusses the Pall GeneDisc during the PDA Annual Meeting








LinkedIn
Twitter
Facebook